Heroin Withdrawal. Mental and behavioural disorders due to use of opioids
Conditions
Interventions
Intervention 1: Olanzapine, 5-15 mg/day, plus placebo of sodium valproate for 12 weeks. Intervention 2: Sodium valproate, 600-1000 mg/day, plus placebo of Olanzapine for 12 weeks.
Treatment - Drugs
Olanzapine, 5-15 mg/day, plus placebo of sodium valproate for 12 weeks
Sodium valproate, 600-1000 mg/day, plus placebo of Olanzapine for 12 weeks
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Methadone Maintenance Treatment, at least one month negative morphine test, age 18 to 55 years old Exclusion Criteria: Axis I Diagnosis of mental disorders, Diabetes Mellitus or impaired glucose tolerance test, Hyperlipidemia, Hepatic Diseases, abnormal CBC, Positive pregnancy test for women
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Aggression. Timepoint: weekly for 12 weeks. Method of measurement: Modified Overt Aggression Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Relapse rate, and side effects. Timepoint: randomly, 1 to 8 times per month urine test for relapse rate; and weekly evaluation of side effects. Method of measurement: urine test for relapse evaluation; and physical and mental status examination for side effects. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMehran Zarghami
Mazandaran University of Medical Sciences
Outcome results
None listed